Novavax Inc. Stock
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novavax Inc. | 97.310% | 80.837% | 108.011% | 0.917% | 84.927% | -93.750% | 26.254% |
Ardelyx Inc. | -3.860% | -10.646% | 8.770% | 81.814% | 24.879% | 33.667% | - |
Evolus Inc | -1.650% | -3.252% | 1.709% | 39.181% | 31.492% | 59.732% | - |
Salarius Pharmaceuticals Inc. | 2.480% | -8.811% | 2.985% | -70.216% | -25.405% | -98.392% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
Why Novavax Stock More Than Doubled Today
Shares of Novavax (NASDAQ: NVAX) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's
Better Buy: Bluebird Bio Vs. Novavax
If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop